Overview

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Patients with multiple myeloma (a type of blood cancer affecting the white blood cells) or amyloidosis (abnormal buildup of a protein called amyloid in the body) are often given treatment with the drugs lenalidomide or pomalidomide. Some patients may experience an allergic reaction to these drugs which would mean stopping the treatment. The purpose of this research study is to see how safe and useful desensitization is in allowing patients to receive further treatment with lenalidomide or pomalidomide.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Lenalidomide
Pomalidomide
Thalidomide